Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN STEINGO

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1417907163
CMS profile
154504
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$64,335.67

177 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN STEINGO

NPI 1417907163 · CMS profile ID 154504

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417907163?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN STEINGO, NPI 1417907163, CMS profile ID 154504. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417907163?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BRIAN STEINGO, NPI 1417907163, CMS profile ID 154504. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417907163?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BRIAN STEINGO, NPI 1417907163, CMS profile ID 154504, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 177 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1417907163?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

177 matching records · $64,335.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 177 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 177.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Aucta Pharmaceuticals, Inc. $28.4205/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1253618683 CMS
Alexion Pharmaceuticals, Inc. $1,775.0005/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202954340 CMS
EMD Serono, Inc. $8,627.5005/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1236867992 CMS
Lundbeck LLC $29.3405/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251850641 CMS
EMD Serono, Inc. $12.8205/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236925776 CMS
UCB, Inc. $29.3305/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224442417 CMS
TG Therapeutics, Inc. $24.6405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226213308 CMS
Alexion Pharmaceuticals, Inc. $20.6505/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202972846 CMS
Biogen, Inc. $52.6905/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208398277 CMS
Biogen, Inc. $21.2205/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208405103 CMS
Alexion Pharmaceuticals, Inc. $18.0105/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202916329 CMS
Alexion Pharmaceuticals, Inc. $20.5805/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202937140 CMS
Alexion Pharmaceuticals, Inc. $3,550.0005/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202954648 CMS
Alexion Pharmaceuticals, Inc. $2.3205/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202963872 CMS
Genentech USA, Inc. $24.1305/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499443 CMS
EMD Serono, Inc. $44.3905/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236901210 CMS
UCB, Inc. $1.9404/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224442413 CMS
UCB, Inc. $31.5104/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224442415 CMS
ACADIA Pharmaceuticals Inc $22.4004/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247801531 CMS
Biogen, Inc. $16.7004/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208405044 CMS
ANI Pharmaceuticals, Inc. $21.1904/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248648788 CMS
GENZYME CORPORATION $29.9404/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233207637 CMS
Neurocrine BioSciences, Inc. $22.3204/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243016436 CMS
ACADIA Pharmaceuticals Inc $17.1404/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247801527 CMS
EMD Serono, Inc. $23.2104/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236903681 CMS
Genentech, Inc. $39.3704/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499459 CMS
Alexion Pharmaceuticals, Inc. $2.3204/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202913764 CMS
Alexion Pharmaceuticals, Inc. $58.6604/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202956378 CMS
Alexion Pharmaceuticals, Inc. $21.9404/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202956896 CMS
Alexion Pharmaceuticals, Inc. $3,550.0004/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202961014 CMS
Biogen, Inc. $10.7504/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208456231 CMS
Lundbeck LLC $20.1404/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251850639 CMS
EMD Serono, Inc. $15.9904/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236921011 CMS
EMD Serono, Inc. $31.5004/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236873620 CMS
EMD Serono, Inc. $89.9904/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236896738 CMS
EMD Serono, Inc. $74.9904/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236900729 CMS
EMD Serono, Inc. $319.2604/04/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1236916518 CMS
EMD Serono, Inc. $184.9904/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236918336 CMS
SCILEX PHARMACEUTICALS INC. $14.0803/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242592383 CMS
GENZYME CORPORATION $11.3903/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233207625 CMS
UCB, Inc. $35.7103/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224442411 CMS
EMD Serono, Inc. $21.7203/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236905197 CMS
EMD Serono, Inc. $110.0003/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236881675 CMS
ANI Pharmaceuticals, Inc. $14.8303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248617865 CMS
Alexion Pharmaceuticals, Inc. $3,550.0003/06/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1202915983 CMS
Genentech USA, Inc. $33.0103/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1211499445 CMS
Alexion Pharmaceuticals, Inc. $20.5803/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1202958680 CMS
EMD Serono, Inc. $46.4103/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236898625 CMS
GENZYME CORPORATION $40.9102/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233207639 CMS
TG Therapeutics, Inc. $7.9202/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226213136 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $241,374.39 440
PY2020 $95,391.39 199
PY2021 $125,374.11 279
PY2022 $130,574.82 309
PY2023 $71,140.47 204
PY2024 $64,014.97 194
PY2025 $64,335.67 177

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $12,097.86 3
PY2025 Principal investigator $275,714.87 18
PY2024 Recipient $1,080.75 1
PY2024 Principal investigator $105,189.12 9
PY2023 Recipient $5,790.65 7
PY2023 Principal investigator $211,277.15 29
PY2022 Recipient $1,547.00 2
PY2022 Principal investigator $1,238,041.53 25
PY2021 Recipient $750.00 2
PY2021 Principal investigator $1,167,763.92 22
PY2020 Recipient $392.71 2
PY2020 Principal investigator $471,108.85 18
PY2019 Recipient $5,838.52 16
PY2019 Principal investigator $373,775.22 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $3,314.00 11/17/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082982
Principal investigator 1 GENZYME CORPORATION $6,544.00 09/29/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082969
Principal investigator 1 GENZYME CORPORATION $19,000.00 08/25/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
A Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Participants With Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226082950
Principal investigator 1 GENZYME CORPORATION $1,657.00 08/04/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082935
Recipient Novartis Pharmaceuticals Corporation $3,097.86 07/18/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190293475
Principal investigator 1 GENZYME CORPORATION $5,638.00 07/02/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082931
Recipient F. Hoffmann-La Roche AG $4,500.00 06/15/2025 Covered Recipient Physician Satralizumab Treatment in Patients With AQP4-IgGSeropositive Neuromyelitis Optica Spectrum Disorder After Rituximab Treatment: A Case Series No dispute reported 06/30/2026 1211534963
Principal investigator 1 GENZYME CORPORATION $3,062.00 05/19/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082925
Principal investigator 1 GENZYME CORPORATION $24,000.00 05/19/2025 Non-covered Recipient Entity
Infinity Clinical Research Sunrise
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226149636
Principal investigator 1 GENZYME CORPORATION $3,062.00 04/21/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082908
Principal investigator 1 EMD Serono, Inc. $375.00 04/10/2025 Non-covered Recipient Entity
Infinity Clinical Research LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118357
Recipient F. Hoffmann-La Roche AG $4,500.00 03/31/2025 Covered Recipient Physician Satralizumab Treatment in Patients With AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder After Rituximab Treatment: A Case Series No dispute reported 06/30/2026 1211534967
Principal investigator 1 GENZYME CORPORATION $8,278.00 03/17/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082881
Principal investigator 1 Novartis Pharmaceuticals Corporation $88,809.46 02/28/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190308584
Principal investigator 1 GENZYME CORPORATION $6,000.00 02/10/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082897
Principal investigator 1 Novartis Pharmaceuticals Corporation $53,889.41 01/31/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190308582
Principal investigator 1 GENZYME CORPORATION $1,950.00 01/27/2025 Non-covered Recipient Entity
Infinity Clinical Research Sunrise
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226149543
Principal investigator 1 GENZYME CORPORATION $6,850.00 01/24/2025 Non-covered Recipient Entity
Infinity Clinical Research Sunrise
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226149549
Principal investigator 1 EMD Serono, Inc. $826.00 01/13/2025 Non-covered Recipient Entity
Infinity Clinical Research LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118361
Principal investigator 1 GENZYME CORPORATION $15,810.00 01/13/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226082893
Principal investigator 1 Amgen Inc. $26,650.00 01/09/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety Between ABP 692 and Ocrevus (Ocrelizumab) in Subjects With Relapsing-remitting Multiple Sclerosis No dispute reported 06/30/2026 1246645036